Differentiating Patient Subtypes to Improve Clinical Trial Design

Time: 11:45 am
day: Day One


  • Linking patient subtypes with underlying proteomic, genomic and microbial mechanisms to clinical trials, addressing the appropriate therapeutic target to improve therapeutic responses
  • Discussing novel biomarkers with the potential to advance IBD clinical trial design with a specific focus on informing inclusion and exclusion criteria
  • Identifying subtype specific disease monitoring markers to demonstrate drug efficacy and support treatment costs